[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100468653":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":29,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":10,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Banaras Hindu University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Head neck cancer",null,"Histologically diagnosed cases of head and neck cancer",[13],"Other: Next generation Sequencing",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Next generation Sequencing","Next generation sequencing for 161 genes",[9],[20],{"name":21,"affiliation":22,"role":23},"Manoj Pandey, MS, PhD","Professor","PRINCIPAL_INVESTIGATOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","9336363640","manojpandey66@gmail.com",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Varanasi","Uttar Pradesh","221005","India","IN",{"type":38,"coordinates":39},"Point",[40,41],83.01041,25.31668,{"lat":41,"lon":40},[44],{"name":45,"role":26,"phone":46,"phoneExt":10,"email":47},"Keshav Murthy, MS","9035424293","keshav.murthy.bmcri@gmail.com",{"type":23,"investigatorFullName":49,"investigatorTitle":22,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Manoj Pandey","100468653","newer-therapeutic-targets-in-head-and-neck-cancers-100468653",false,"NCT05382585","Newer Therapeutic Targets in Head and Neck Cancers","A Cohort Study to Identify Newer Therapeutic Targets in Head and Neck Cancers","Inclusion Criteria:\n\n* Histologically proven cases of primary head and neck cancers.\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Pregnant and lactating women\n* Multiple cancers or patients with cancer of other sites.","ALL","18 Years","100 Years",{"count":61,"type":62},200,"ESTIMATED","OBSERVATIONAL","Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes:\n\n1. cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA);\n2. cell-cycle control (e.g., CDKN2A and CCND1);\n3. cellular differentiation (e.g., NOTCH1); and\n4. Adhesion and invasion signaling (e.g., FAT1).7 TP53, EGFR, PIK3CA, CDKN2A, CCND1, and MET participate in several common signaling pathways.\n\nAlterations of these genes are most frequently seen in alcohol and tobacco-related HNSCC. However their role in prognostication and selection of therapeutics is not known",[66,67],"Head Neck Cancer","Oral Cancer",[69,70],"Next generation sequencing","predictive biomarker","2024-08-09",{"date":73,"type":74},"2024-08-13","ACTUAL",{"date":76,"type":74},"2017-04-01",{"date":78,"type":62},"2027-12-31",{"name":5,"class":6},1]